Poland· PL-100309668
Eurartesim
A artenimol und piperaquin product containing piperaquini tetraphosphas + dihydroartemisininum, registered in Poland by Alfasigma S.p.A.. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Artenimol und piperaquin is registered in 9 of 19 countries.
Countries holding a registration under ATC P01BF05 (artenimol und piperaquin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Artenimol und piperaquin · ATC P01BF05
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Piperaquini tetraphosphas + Dihydroartemisininum
- Manufacturer
- Alfasigma S.p.A.
- Country
- Poland (PL)
- ATC code
- P01BF05
- ATC class
- Artenimol und Piperaquin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Artenimol und piperaquin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandEurartesim 160 mg/20 mg film-coated tabletsSigma-Tau Industrie Farmaceutiche Riunite SpA
- IcelandEurartesimAlfasigma S.p.A.
- NetherlandsEurartesim 160 mg/20 mg filmomhulde tablettenAlfasigma S.p.A
- FinlandEurartesimALFASIGMA S.p.A.
- FranceEURARTESIM 320 mg/40 mg, comprimé pelliculéALFASIGMA (ITALIE)
- United KingdomEurartesim 320mg/40mg tabletsLogixx Pharma Solutions Ltd
- SpainEURARTESIM 320 mg/ 40 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAlfasigma S.P.A.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/97d65a9e-10b8-44fb-8c49-03d065ebfe47 GET /v1/drugs/97d65a9e-10b8-44fb-8c49-03d065ebfe47?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "320 mg + 40 mg",
"packaging": "Rp ¦ EU/1/11/716/001 ¦ 88857\n3 tabl.\nRp ¦ EU/1/11/716/002 ¦ 88858\n6 tabl.\nRp ¦ EU/1/11/716/003 ¦ 88859\n9 tabl.\nRp ¦ EU/1/11/716/004 ¦ 88860\n12 tabl.\nRp ¦ EU/1/11/716/007 ¦ 148849\n300 tabl.\nRp ¦ EU/1/11/716/006 ¦ 148850\n270 tabl.",
"substance": "Piperaquini tetraphosphas 320 mg + Dihydroartemisininum 40 mg",
"common_name": "Piperaquini tetraphosphas + Dihydroartemisininum",
"pl_product_id": "100309668",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about artenimol und piperaquin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.